Big pharma, Partnering, Pharma

Teva and Takeda enter into a pharma licensing deal in Japan

Posted on 05 December 2013

Tags: , , , ,

Teva entered pharma licensing with Takeda  to commercialize Teva’s innovative glatiramer acetate formulation for the treatment of multiple sclerosis, in Japan.

Teva and Takeda are currently working on further agreements in connection with the implementation of this licensing deal.

Teva’s glatiramer acetate is designated as an orphan drug in Japan.

Under development as an Unapproved New Drug by Teva Pharmaceutical at the request of the Japanese Ministry of Health, Labor and Welfare.

Teva will grant Takeda commercialization rights in Japan, and Takeda will submit a New Drug Application for registration of glatiramer acetate in Japan.

The financial details of the agreement are confidential.

Read the full article on Business Wire

For further deal information visit Current Agreements (subscription required)



Report: Orphan Drugs Partnering Agreements Terms and Agreements

Report: Partnering Deals and Alliances with Takeda

Report: Partnering Deals and Alliances with Teva

Browse: Complete Current Partnering report catalog

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter - reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

Print Friendly, PDF & Email

Leave a Reply